Schroder Investment Management Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Schroder Investment Management Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,876	Closed	-$87.8K	–	1257
2024 Q4	$87.8K	Sell	11,876 -3,421	-22%	-$23K	﹤0.01%	1186
2024 Q3	$101K	Buy	+15,297	New	+$110K	﹤0.01%	1180
2023 Q2	–	Sell	-131,803	Closed	-$879K	–	1277
2023 Q1	$879K	Sell	131,803 -28,161	-18%	-$223K	﹤0.01%	1069
2022 Q4	$1.23M	Buy	159,964 +51,119	+47%	+$501K	﹤0.01%	1027
2022 Q3	$1.16M	Buy	+108,845	New	+$1.1M	﹤0.01%	1030

Other funds holding RXRX

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Schroder Investment Management Group's RXRX Position: Q1 2025 in Review

Schroder Investment Management Group sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 11,876 shares — an estimated $87.8K sold.

Schroder Investment Management Group first reported a position in RXRX in Q3 2022 and held it in 5 quarters. The position peaked at $1.23M in Q4 2022. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

Schroder Investment Management Group reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Schroder Investment Management Group sold 11,876 Recursion Pharmaceuticals shares in Q1 2025, an estimated $87.8K.
Schroder Investment Management Group first reported a position in Recursion Pharmaceuticals in Q3 2022 and held it in 5 quarters.
Schroder Investment Management Group's Recursion Pharmaceuticals position peaked at $1.23M in Q4 2022.
336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Schroder Investment Management Group's 13F filing for Q1 2025, filed 13 May 2025.